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GliomaDespite extensive investigation into the role of let-7 miRNAs in pathological tumor processes, their
involvement in the DNA damage response remains unclear. Here we show that most let-7 family
members down-regulate MDM4 expression via binding to MDM4 mRNA at a conserved DNA
sequence. Expression of exogenous let-7 miRNA mimics decreased MDM4 protein but not mRNA
levels. Several DNA damage reagents increased let-7 expression, thereby decreasing MDM4 protein
levels in glioma cells. Inhibition of endogenous let-7 with antisense RNAs rescued MDM4 protein
levels with or without MG132, a proteasome-dependent degradation inhibitor. An MDM4 mutation
identiﬁed in a glioma patient was associated with loss of the putative MDM4 target site. Therefore,
let-7 binding to MDM4 is implicated in the DNA damage response.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are small non-coding RNAs that mediate
sequence-speciﬁc gene expression at the post-transcriptional level
by targeting the 30 untranslated region (30UTR) or the putative cod-
ing DNA sequence (CDS) [1]. Recently, many studies have impli-
cated miRNAs in the regulation of genome stability and the
response to DNA damage. For instance, miR-24 is upregulated in
the terminal differentiation of hematopoietic cell lines and inhibits
the histone variant H2AX, which causes the terminal differentia-
tion of hematopoietic cells hypersensitive to gamma-irradiation
and genotoxic drugs [2]. miR-138 can target H2AX, affecting geno-
mic stability [3]. The miRNA miR-182 suppresses BRCA1 to impede
homologous recombination [4]. In general, let-7 acts as a tumor
suppressor in various cancers. Nine let-7 family members exist in
human cells, including let-7a, let-7b, let-7c, let-7d, let-7e, let-7f,
let-7g, let-7i and miR-98 [5]. Let-7 can inhibit tumor cellproliferation, the efﬁciency of colony formation [6] and the
epithelial-mesenchymal transition [7]. Consequently, the let-7
expression level can indicate the stage of cancer [7]. Let-7 can also
inﬂuence genomic stability [8,9], and the expression level of let-7
in tumors is related to survival after chemotherapy and radiother-
apy [10,11]. It seems that high let-7 expression could induce tumor
cell death when DNA damage is irreparable.
Several studies have shown that the expression levels of let-7
family members are signiﬁcantly altered by DNA damage.
However, different cell types exhibit different changes in let-7
expression after irradiation. In the human glioma cell line
M059K, the expression levels of all let-7 family members were
increased after radiation [12]. In the Jurkat p53-negative human
T lymphocyte cell line, ionizing radiation can induce increases in
all let-7 family members. In the p53-positive TK6 cell line, let-7a,
let-7b, let-7c and let-7f were increased after radiation [13].
Let-7a, let-7c, let-7d, and let-7g were shown to be upregulated in
normal human thyroid cells by irradiation [14]. Recently, Lee et
al. showed that stimulation of p53 by a DNA damage agent can
increase let-7 levels by downregulating Lin28A [15]. However,
let-7a and let-7b expression levels were reported to be decreased
in the human colon cancer cell line HCT116 in a p53-dependent
manner after various types of DNA damage including irradiation,
ultraviolet radiation, etoposide and hydrogen peroxide [16].
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tumor formation by inhibiting p53 activity [18]. MDM4 is one of
the well-characterized molecules that can play an important role
in regulating genomic stability [19]. DNA damage could rapidly
reduce the half-life of MDM4 [20]. Some experiments support
the conclusion that MDM4 is phosphorylated by ATM and Chk2
and then degraded by MDM2 and the proteasome [20]. However,
when the proteasome is inhibited, MDM4 levels could still
decrease after DNA damage [21], suggesting that another MDM4
repression pathway exists, such as an miRNA pathway. The
miRNAs miR-191, miR-10a, miR-15 and miR-34a were reported
to target MDM4 and repress the level of MDM4 protein [21–24].
In addition, miR-191 is highly expressed in both normal and tumor
tissues. A single nucleotide polymorphism (SNP) in the 30UTR of
MDM4 causes the loss of an miR-191 target site, which is associ-
ated with a poor ovarian cancer prognosis [24].
Despite extensive investigation into the roles of let-7 miRNA
family members in various pathological tumor processes and a
study showing that let-7 could inhibit glioma cell growth and
migration [25], the role of let-7 after DNA damage in glioma has
not been fully characterized. This study demonstrates that let-7
could suppress MDM4 expression and that MDM4 is downregu-
lated through an increase in let-7 expression in U87 and A172
glioma cells after DNA damage induced by cisplatin, bleomycin
and hydroxyurea. Furthermore, the results demonstrate that a
mutation in the let-7-MDM4 target site found in a human glioma
sample might affect let-7 binding at the MDM4 CDS.
2. Materials and methods
2.1. Bioinformatic analysis
DIANA LAB, RegRNA, microRNA, RNAhybrid and PITA software
were used to predict the miRNA targets of MDM4. The clustal W
algorithm was used for multiple sequence alignment analysis.
2.2. Cell culture
Human glioma cell lines (U87 and A172) were purchased from
American Type Culture Collection (Manassas, VA, USA). Cells were
cultured in DMEM (Invitrogen, Carlsbad, CA, USA) containing 10%
(V/V) fetal bovine serum (FBS, Invitrogen), 100 U/ml penicillin
and 100 lg/ml streptomycin (Invitrogen, Carlsbad, CA, USA) with
5% CO2 at 37 C.
2.3. Vector construction and transfection
To express miRNAs, pre-miRNAs with 80–150 bp of ﬂanking
sequences at both ends were cloned into the modiﬁed pLL3.7 vec-
tor under the control of the human U6 promoter using the primers
listed in Table S1. To construct luciferase reporter vectors, MDM4
CDS wild type or mutated sequences corresponding to the pre-
dicted miRNA target sites were synthesized using the sequence
listed in Table S1 and cloned downstream of Renilla luciferase in
the psiCHECK-2 vector (Promega, Madison, WI, USA).
Let-7a, let-7c mimics, antisense RNAs and their cognate control
RNAs were synthesized and puriﬁed by GenePharma, China. Cell
transfection was performed using X-tremeGENE siRNA
Transfection Reagent (Roche, Rotkreuz, Switzerland) according to
the manufacturer’s instructions. Transfections were carried out
with 100 nmol/L of miRNA mimics or 200 nmol/L of antisense
oligonucleotides. The efﬁciency of small RNA transfection was esti-
mated to be greater than 95% for U87 and A172 cells using a Cy3
dye-labeled RNA oligonucleotide (Ribobio, Guangzhou, China).
FuGENE HD (Roche, Rotkreuz, Switzerland) was used for plasmidtransfection according to the manufacturer’s instructions. DNA
(400 ng) was added in a 96-well plate. miRNA expression vectors
and reporter constructs were co-transfected at a 3:1 ratio.
2.4. RNA extraction and real-time quantitative RT-PCR
Total RNA was extracted from cells using Trizol (Invitrogen,
Carlsbad, CA, USA), reverse-transcribed with Rever-Tra-Ace-a-Tra
nscriptase (Toyobo, Tokyo, Japan) and then ampliﬁed by PCR using
the SYBR Premix Ex Taq™ II (Tli RNaseH Plus) (Takara, Tokyo,
Japan). RNAs were quantiﬁed and checked for purity by spec-
trophotometry at 260 and 280 nm. Real-time quantiﬁcation of
microRNAs by stem-loop RT-PCR was carried out using U6 snRNA
as an internal standard. The primer sequences are listed in
Table S1.
Quantitative PCR was performed on a LightCycler 480
Real-Time PCR system (Roche, Rotkreuz, Switzerland).
Relative-fold changes in miRNA or mRNA expression in treated
cells compared with control cells were calculated using the com-
parative Ct (2DDCt) method [26]. All reactions were performed
in triplicate.
2.5. Western blotting
Cells were lysed in RAPI lysis buffer (Bioteke, Beijing, China),
and the whole-cell protein concentration was determined by a
bicinchoninic acid protein assay kit (Beyotime, Shanghai,
China). Protein samples (20 lg per lane) were denatured and
separated by SDS–polyacrylamide gel electrophoresis (PAGE) on
a 12% gel and then transferred to a PVDF membrane
(Millipore, Bedford, MA, USA). The membrane was incubated
overnight at 4 C with a primary antibody and then incubated
for 1 h with secondary antibody. The bound antibody was
detected using enhanced chemiluminescence detection reagents
(Pierce, Rockford, IL, USA) according to the manufacturer’s
instructions. The band intensities were quantiﬁed with Kodak
Image Station 4000 MM Pro (Kodak, Tokyo, Japan).
Anti-human MDM4 and b-actin were purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Anti-Human
c-H2AX was purchased from Millipore (Bedford, MA, USA).
Goat-anti-mouse and goat-anti-rabbit were purchased from
Jackson ImmunoResearch (West Grove, PA, USA).
2.6. Dual-luciferase reporter assays
For the luciferase reporter assay, 2.0  104 293T cells were pla-
ted in 100 lL growth medium in 96-well plates. The cells were
transfected with 100 ng reporter plasmids and 300 ng miRNA
expression plasmids using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) or FuGENE (Roche, Rotkreuz, Switzerland).
The cells were harvested 48 h after transfection and assayed using
the dual-luciferase reporter assay kit (Promega, Madison, WI, USA)
according to the manufacturer’s instructions. Transfections were
repeated in triplicate.
2.7. Drug treatment
U87 or A172 cells were seeded in 3.5 cm dishes at 2  105 cells
per dish, incubated overnight, and then treated with the reagents
of interest for various periods of time. Cisplatin (Sigma, St. Louis,
MO, USA) was dissolved in 0.9% NaCl before use and was added
to the cell culture medium at various ﬁnal concentrations.
Bleomycin (Aladdin, Shanghai, China) and hydroxyurea (Sigma,
St. Louis, MO, USA) were dissolved in sterile water and stored at
20 C.
Fig. 1. Let-7 miRNA family members can target the MDM4 CDS. (A) The predicted
target sequence of let-7 family members within the human MDM4 CDS. (B)
Alignment of human and other species MDM4 DNA binding sites to let-7 family
members. (C) The effect of different let-7 family members on MDM4 CDS reporter
constructs in HEK293T cells was tested by a luciferase reporter assay. The data were
normalized to the ratio of Fireﬂy and Renilla luciferase activities measured at 48 h
post-transfection. Rno-miR-344 (pll3.7-miR-344) is an miRNA that does not have
homologue in humans. The results were presented as relative luciferase activity,
with the control assigned a value of 1. Values represent the mean ± S.D. from three
independent transfection experiments. Signiﬁcant differences from the control
value are indicated by ⁄, P < 0.05, ⁄⁄, P < 0.01.
1960 C. Xie et al. / FEBS Letters 589 (2015) 1958–19652.8. Statistical analysis
Data analysis was performed using Origin 8.0 (ADITIVE,
Friedrichsdorf, Germany) and Excel software (Microsoft,
Redmond, WA, USA), and results are presented as the mean ± stan-
dard deviation (S.D.) of at least three separate experiments.
Statistical analyses were performed using analysis of variance or
Student’s t test. P values < 0.05 were considered statistically signif-
icant (⁄, P < 0.05; ⁄⁄, P < 0.01).
3. Results
3.1. Let-7 miRNA family members repress MDM4 expression
Bioinformatic analysis predicted that all let-7 family members
target the human MDM4 CDS (456–474) (Fig. 1A). The putative
let-7 target site is conserved when aligning the sequences of mam-
mals and other species (Fig. 1B). To investigate whether the
expression of let-7 family members correlates with MDM4 expres-
sion, we ﬁrst constructed expression vectors for let-7 miRNA fam-
ily members. Each miRNA expression vector and two controls
(empty vector (pll3.7-control) and rno-miR-344 (pll3.7-miR-344),
a microRNA that does not have a homologue in humans) were
co-transfected with an MDM4 CDS reporter vector, and then a
dual-luciferase assay was used to determine the decline in the rel-
ative luciferase activity resulting from transfection with let-7 fam-
ily members compared with the control (Fig. 1C). As let-7c and
let-7a lead to the greatest inhibition, we analyzed these two
microRNAs further. To validate whether MDM4 is directly targeted
by let-7 family members, we constructed ﬁve different mutations
of the putative let-7-binding site in the MDM4 CDS reporter
(MT1-MT5) (Fig. 2A). The results of the dual-luciferase assay
showed that neither let-7a nor let-7c can suppress the expression
of the mutated constructs as effectively as they suppress the wild
type constructs (Fig. 2B and C). In addition, each let-7 family mem-
ber was co-transfected with the MT5 CDS to further characterize
the interaction. As expected, the introduction of silent mutations
into predicted targets disrupted the ability of the miRNAs let-7a,
let-7b, let-7c, let-7e and let-7g to repress the expression of the
luciferase reporter, with the MT5 reporter expressing higher levels
of luciferase than the wild type reporter (Fig. 2D). Taken together,
these results indicate that these miRNAs could directly target the
MDM4 CDS.
To determine whether let-7 can disrupt endogenous MDM4
expression in glioma cells, let-7a and let-7c mimics were trans-
fected into U87 cells. qRT-PCR results showed that the expression
levels of let-7a and let-7c were approximately six to nine times
higher compared to the control (Fig. 2E). A Western blot assay
showed that both let-7a and let-7c consistently and substantially
downregulated the expression level of the MDM4 protein without
affecting its mRNA level in U87 cells (Fig. 2E), indicating that let-7a
and let-7c mainly impair MDM4 expression through translational
inhibition. Furthermore, similar experiments were performed
using let-7a and let-7c antisense treatment, and decreases in
let-7a and let-7c increased the MDM4 protein level without chang-
ing the mRNA level (Fig. 2F).
3.2. DNA damage decreased MDM4 expression, partially via let-7
The MDM4 protein is associated with the DNA damage response
[20]. We hypothesized that the reduction of MDM4 after DNA
damage was mediated by let-7 family members. A Western blot
showed that the level of the MDM4 protein was signiﬁcantly
decreased following treatment with different doses of cisplatin
(CDDP) for 24 h in U87 cells (Fig. S1), where phosphorylatedH2AX (p-H2AX) was used as a marker of DNA damage. In addition,
qRT-PCR was used to determine the expression level of let-7. The
miRNA expression level of most let-7 family members increased
signiﬁcantly after U87 cells were treated with 2.5 lM CDDP
(Fig. 3A). Interestingly, we found that the changes in the let-7
and MDM4 protein levels were inversely correlated
(Fig. 3A and B). To conﬁrm these results, A172 glioma cells were
used in the same experiment. The results showed that the expres-
sion levels of let-7a and let-7c were increased, whereas the level of
MDM4 protein was decreased when the A172 glioma cells were
Fig. 2. The let-7 miRNA family members directly correlate with MDM4. (A) Sequences of MDM4 CDS (WT) and mutations (MT1-MT5). Several nucleotides within the seed
region as well as other predicted binding regions were mutated in the MDM4 sequence. (B and C) Empty vector (pll3.7-control) or miRNA expression vector (pll3.7-let-7a or
pll3.7-let-7c) were co-transfected with MDM4 or mutants MT1-MT5. Luciferase activity was measured at 48 h post-transfection. Each data point was measured in triplicate.
(D) Let-7 family members were co-transfected with MDM4 CDS mutant expression vectors (MT5) or wild type MDM4 CDS, respectively. (E and F) miRNA (let-7a or let-7c)
mimics or antisense RNAs were transfected into U87 cells. Relative expression levels of let-7a, let-7c and MDM4were determined by qRT-PCR 48 h after transfection. Western
blot was used to analyze the MDM4 protein level. b-actin served as the internal control. Values represent the means ± S.D. Signiﬁcant differences from the control value are
indicated by ⁄, P < 0.05, ⁄⁄, P < 0.01.
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results for U87 glioma cells (Fig. 3C).
To determine whether let-7 repression of MDM4 could also
mediate DNA damage induced by other reagents, bleomycin and
hydroxyurea were used to induce DNA damage instead of CDDP.
The results in U87 and A172 glioma cells showed that theexpression levels of let-7a and let-7c were increased after treat-
ment with bleomycin or hydroxyurea, and MDM4 protein level
was reduced (Fig. 4A–D).
To better understand the role of let-7 in the repression of
MDM4 in response to DNA damage, we transfected let-7a and
let-7c antisense RNAs to inhibit these miRNAs in U87 and A172
Fig. 3. Cisplatin treatment results in a change in let-7 and MDM4 expression. (A)
Expression level of let-7 family members was measured by qRT-PCR after cisplatin
(CDDP) treatment. miR-34a served as a positive control, and miR-125b and miR-
135b served as negative controls. (B) Western blot analysis of the MDM4 protein
level after CDDP treatment. p-H2AX acted as a DNA damage marker. b-actin served
as the internal control. (C) A172 cells were treated with 10 lM CDDP for 24 h, and
then the MDM4 protein level was measured by Western blot and the relative
expression levels of let-7a and let-7c were determined by qRT-PCR. Natural saline
(NS) served as a negative control.
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ative MDM4 protein level increased (Fig. 4E and F), indicating that
decreasing let-7a or let-7c can eliminate the effect of CDDP treat-
ment on the MDM4 protein. Furthermore, inhibition of proteasome
degradation by pretreatment of U87 cells with 5 lM of MG132
does not completely block the reduction in the level of the
MDM4 protein following CDDP treatment (Fig. 4G). Taken together,
these results suggest that rather than proteasome degradation,
let-7 family members may play a key role in mediating the
decrease in the level of the MDM4 protein after DNA damage.3.3. A mutation found in glioma may disrupt the relationship between
let-7 and MDM4
The Cancer Genome Atlas Research Network has shown that the
Thr160Ser missense mutation of MDM4 is found in human glioma
[27]. As Thr and Ser have a similar structure and this missense
mutation exists in the seed region of the let-7-MDM4 target site,
we proposed that this mutation might contribute to the disruption
of the let-7 repression of MDM4. To test this hypothesis, we dis-
rupted the target site by mutating 160Thr (ACC) to 160Ser with
the AGC (observed in a glioma patient), TCG, AGT or TCC codons
(Fig. 5A). As all these mutations code for Ser, the latter three muta-
tions were used to test whether a change in one or two bases could
disrupt the let-7 repression of MDM4. Then, the let-7 expression
vector was co-transected with the MDM4 CDS reporter construct
and a dual-luciferase assay was followed. The results showed that
the repressive effect of let-7 family members on luciferase activity
was inhibited by a single C to G transition, the mutation observed
in a glioma patient (Fig. 5B). The repressive effect of let-7a and
let-7c on luciferase activity was also inhibited by all other mis-
sense mutations TCG (S1), AGT (S2) and TCC (S3) (Fig. 5C and D).
These results suggest that these mutations may disrupt the let-7
repression of MDM4.
4. Discussion
Cells overexpressing let-7 have been reported to be hypersensi-
tive to DNA damage [28]. Several studies have shown that let-7
family members are upregulated after DNA damage [12–14,29],
although in some cells the let-7 family members are downregu-
lated by DNA damage [16]. In this study, we found that the let-7
expression level in glioma cells was upregulated after DNA dam-
age, which, in turn, suppressed MDM4 expression.
Although the alterations in the let-7 expression level after DNA
damage have been widely observed, the mechanisms of this pro-
gress remain unclear. To explain this phenomenon, Chaudhry et
al. proposed that the increase in let-7 after DNA damage may be
mediated by a DNA-dependent serine/threonine protein kinase in
glioma cell lines [12]. Lin28 is a well-known gene that can inhibit
the maturity of let-7 [30]. Recently, Lee et al. showed that DNA
damage increased let-7 levels through downregulation of Lin28A
[15]. KSRP was also reported to interact with Drosha and Dicer to
promote the maturity of let-7a [31]. KSRP accumulates in the
nucleus when Hela cells are cultured with cisplatin [32], which
may suggest that KSRP mediates the change in let-7 expression.
Further study should focus on the role of KSRP and Lin28A in the
process of let-7 maturation in glioma cells.
Approximately 40% of gliomas exhibit a p53 mutation or dele-
tion, and approximately 80% of gliomas have a p53 pathway defect
[33]. In response to DNA damage, MDM4 expression is downregu-
lated and contributes to p53 activation [20]. Post-translationalmod-
iﬁcations are considered to play an important role in MDM4
regulation after DNA damage. For example, MDM4 is ﬁrst phospho-
rylated by ATM and Chk2 and then degraded byMDM2 and the pro-
teasome after DNA damage [20]. However, even after suppressing
MDM4degradation by addingMDM2 siRNAor the proteasome inhi-
bitor MG132, the amount of endogenous MDM4 remains largely
reduced after DNA damage [21]. We also demonstrated that block-
ade of proteasome-dependent degradation with MG132 in U87
and A172 glioma cells cannot suppress the decrease in the endoge-
nous MDM4 protein level after cisplatin treatment (Fig. 4G). All of
these points suggest that there could be exist another mechanism
besides MDM2-mediated proteasome-dependent degradation of
MDM4 after DNA damage. In this study, we show that severalmem-
bers of let-7 family including let-7a, -7c, -7e, -7g and -7i can repress
MDM4 at the protein level. Moreover, knockdown of let-7a and
Fig. 4. DNA damage could interfere with MDM4 expression through let-7. The MDM4 protein level and the relative expression levels of let-7a and let-7c were determined by
Western blot and qRT-PCR, respectively, after treatment with 100 lM bleomycin or 1 mM hydroxyurea for 24 h in U87 cells (A and B) and A172 cells (C and D). PBS served as
the negative control. (E and F) Western blot was used to compare MDM4 protein levels among cells transfected with antisense let-7a, antisense let-7c or a negative control
with or without CDDP in U87 and A172 cells. (G) MG132 was used to block proteasome-mediated MDM4 degradation. Whole cell extracts from the indicated treatment
conditions were subjected to Western blot analysis for MDM4 and b-actin. b-actin served as the internal control.
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(Fig. 2F). This result can be explained as follows: (1) let-7a and
let-7b are the most abundant species in glioma cells [34], knock-
down of let-7a could reduce the total let-7 level signiﬁcantly; (2)
there is only one nucleotide difference between let-7c and let-7a
or let-7b (Fig. 1A), antisense let-7c may exert an effect through
let-7a and let-7b. We also found that the MDM4 protein level
becamemore sensitive to antisense let-7a and let-7c after U87 cells
were treated with MG132 alone or in combination with CDDP than
the same cells without MG132 treatment (Fig. 4G). This may be
because investigating the proteasome degradation inhibited by
MG132 made the role of let-7 in MDM4 regulation more clear.
These genetic traits are always linked to tumorigenesis, tumor pro-
gression and prognosis and chemotherapy. For example, a let-7
binding site polymorphism in the KRAS 30UTR is associated with
reduced survival in oral cancers and metastatic colorectal cancers[35,36]. An SNP in the miR-191 target site within the 30UTR of
MDM4also affects ovarian cancer progression and chemosensitivity
[24]. Consequently, more studies should be carried out to under-
stand the function of mutations or SNPs at miRNA target sites. In
our studies, we demonstrated that a single base mutation identiﬁed
in a glioma patient can disrupt the interaction between let-7 and
MDM4 mRNA. Coincidentally, asynonymous somatic mutation
(COSM1646071 (C/A), Thr(ACC)160Thr(ACA)) also located in this
seed region of the let-7 binding site, was identiﬁed in both human
lung cancer and large intestine cancer samples in the COSMIC pro-
ject (release 71). These results suggest that this binding site is
important for tumor formation or progression.
In summary, this study reports MDM4 as a new target of
let-7,which can bind to the MDM4 CDS and then downregulate the
level of the MDM4 protein. The let-7 expression level was upregu-
lated after DNA damage induced by cisplatin, bleomycin or
Fig. 5. A mutation found in glioma, Thr160Ser, may disrupt the relationship between let-7 and MDM4. (A) Sequences of MDM4 and its missense mutations. One or two
nucleotides underlined within the seed region of the MDM4 sequence were mutated (MT-G, S1, S2 and S3), where MT-G was found in a tumor sample. (B) let-7 family
members were co-transfected with wild type MDM4 or the MT-G mutant. Luciferase activity was measured at 48 h post-transfection. (C and D) Empty vector (pll3.7-control)
or miRNA expression vector (pll3.7-let-7a or pll3.7-let-7c) were co-transfected with MDM4 or mutants S1, S2 or S3. Luciferase activity was measured at 48 h post-
transfection. Each data point was measured in triplicate. Values represent the means ± S.D. Signiﬁcant differences from the control value are indicated by ⁄, P < 0.05, ⁄⁄,
P < 0.01.
1964 C. Xie et al. / FEBS Letters 589 (2015) 1958–1965hydroxyurea in U87 and A172 glioma cell lines. Further, we found
that the reduction of MDM4 after DNA damage can be recovered
by inhibiting the increase in let-7. In addition, a mutation found in
glioma can damage the interaction between let-7 and MDM4.
Furthermore, additional abnormal targets of let-7 in glioma must
be identiﬁed to determine the contributions of let-7 to glioma
tumorigenesis and tumor progress. This result suggests that let-7
directly and functionally targets MDM4, which may relate to the
activation of p53 to maintain genome stability. Therefore,
let-7-based therapy may be beneﬁcial for the clinical treatment of
cancers, including gliomas.
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